BAX - Baxter International
29.50
| Index: | S&P 500 | P/E: | 128.65 | EPS (ttm): | 0.23 | Insider Own: | 0.79% | Shs Outstand: | 510.46M | Perf Week: | -2.70% |
| Market Cap: | 15.38B | Forward P/E: | 11.88 | EPS next Y: | 2.48 | Insider Trans: | 0.00% | Shs Float: | 506.57M | Perf Month: | -9.59% |
| Income(ttm): | 116.00M | PEG: | - | EPS next Q: | 0.52 | Inst Own: | 93.73% | Short Float: | 2.44% | Perf Quarter: | -24.36% |
| Revenue(ttm): | 13.99B | P/S: | 1.10 | EPS this Y: | -29.69% | Inst Trans: | 2.50% | Short Ratio: | 3.04 | Perf Half Y: | -13.72% |
| Book/sh: | 15.42 | P/B: | 1.91 | EPS next Y: | 35.80% | ROA: | -0.52% | Short Interest: | 12.37M | Perf Year: | -23.58% |
| Cash/sh: | 2.72 | P/C: | 10.83 | EPS next 5Y: | -1.06% | ROE: | -1.85% | 52W Range: | 28.62 - 44.01 | Perf YTD: | -23.69% |
| Dividend Est.: | 1.18 (4.01%) | P/FCF: | 27.55 | EPS past 5Y: | - | ROI: | 0.62% | 52W High: | -32.96% | Beta: | 0.60 |
| Dividend TTM: | 1.04 (3.53%) | Quick Ratio: | 1.09 | Sales past 5Y: | 6.04% | Gross Margin: | 36.98% | 52W Low: | 3.09% | ATR (14): | 0.82 |
| Dividend Ex-Date: | Nov 29, 2024 | Current Ratio: | 1.43 | EPS Y/Y TTM: | 139.38% | Oper. Margin: | 9.30% | RSI (14): | 29.14 | Volatility: | 3.03% 2.31% |
| Employees: | 60000 | Debt/Eq: | 1.68 | Sales Y/Y TTM: | -6.44% | Profit Margin: | 0.83% | Recom: | 2.82 | Target Price: | 37.64 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 1.36 | EPS Q/Q: | 136.29% | Payout: | - | Rel Volume: | 3.00 | Prev Close: | 28.90 |
| Sales Surprise: | -29.83% | EPS Surprise: | -36.90% | Sales Q/Q: | -27.21% | Earnings: | Nov 08 BMO | Avg Volume: | 4.07M | Price: | 29.50 |
| SMA20: | -6.61% | SMA50: | -12.62% | SMA200: | -19.04% | Undervalued: 27.59% | Volume: | 12,194,858 | Change: | 2.08% | |
Graham Classic formula value: 1.32
(P/E=8 * 1g) Min value: 1.43
(current P/E * 2g) Max value: 26.13
Average value: 9.63
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.